Canaccord Genuity Initiates Coverage On Kazia Therapeutics with Buy Rating, Announces Price Target of $29

Benzinga Newsdesk www.benzinga.com Neutral 57.6%

Neg 0% Neu 57.6% Pos 0%

Canaccord Genuity analyst John Newman initiates coverage on Kazia Therapeutics (NASDAQ:KZIA) with a Buy rating and announces Price Target of $29.